Primary entity: SLU-PP-915Also known as: slupp-915 (search spelling); compound 10sClass: Pan-ERR agonist — not a peptideCluster: GLP-1 & metabolic
SLU-PP-915 is a research designation for a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), identified in a St. Louis University Pharmaceutical Program (SLU-PP) chemistry series (compound 10s). It is chemically a small molecule (literature describes a boronic-acid-containing thiophene template), not a peptide, and not an FDA-approved drug. Related tool compound SLU-PP-332 is better known in popular “exercise mimetic” coverage; SLU-PP-915 is a sibling pan-ERR agonist characterized for gene-expression and pharmacology work, with later analytical papers mapping metabolism for potential doping-control relevance.
“Slupp-915” is a compacted search spelling of SLU-PP-915, not a different molecule. Neither name is a peptide. ERR agonists are nuclear-receptor ligands — a different class from incretin peptides, SARMs, and PPARδ agonists like cardarine.
Not FDA-approved. No authorized medicine. Evidence base is primarily chemical / in vitro / animal pharmacology plus anti-doping analytical characterization. Explicit year-by-year WADA Prohibited List naming for SLU-PP-915 can lag popular claims — some secondary sources assert forthcoming or list-year naming alongside SLU-PP-332; athletes should treat non-approved exercise-mimetic metabolic agents as high risk and check current WADA list + GlobalDRO, not forums. S0 (non-approved substances) and/or metabolic-modulator class logic may apply even when a code is not spelled out. Gray-market “research” vials/capsules are not clinical trial supply.
Key takeaways
- Not a peptide — pan-ERR agonist small molecule (SLU-PP-915; search spelling slupp-915).
- Naming comes from the St. Louis University Pharmaceutical Program series; paper identity includes compound 10s.
- Sibling curiosity: SLU-PP-332 (often the headline “exercise mimetic” ERR tool) — related, not identical.
- Not FDA-approved; human therapeutic approval pathway not established in the sources cited on this page.
- Anti-doping labs have published metabolism / detection work flagging doping potential — athletes: verify current rules.
- No dosage chart on this site.
Questions this page answers
- What is SLU-PP-915?
- Naming / “slupp-915” spelling
- Classification — why it’s on a peptide site
- What it is NOT
- Mechanism (ERR)
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory & sport snapshot
- Why no dosages
- Related metabolic agents
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who saw “slupp-915” / SLU-PP-915 in forums or AI answers and need naming confirmation, chemistry-class literacy, and evidence-maturity hedges.
Not for: anyone seeking a buy link, an endurance protocol, a stack with SLU-PP-332, or medical advice.
What is SLU-PP-915?
SLU-PP-915 is a potent pan-ERR agonist from a structure-based medicinal-chemistry series designed around ERR pharmacology (building from earlier ERR ligand templates such as acyl-hydrazide / GSK-4716-class starting points in the paper narrative). Optimization introduced a boronic acid moiety associated with retained agonist activity and improved microsomal stability in the authors’ assays. Gene-expression work reported upregulation of ERR target genes (e.g., PGC-1α-pathway-related and metabolic genes such as LDHA / PDK4 / DDIT4 in the paper’s framing) in vitro and in vivo.
| Chemistry class | Pan-ERR (ERRα/β/γ) agonist small molecule |
|---|---|
| Peptide? | No |
| Canonical name | SLU-PP-915 |
| Search spelling | slupp-915 (same entity) |
| Series identity | Compound 10s in identifying chemistry paper |
| Related tool | SLU-PP-332 (sibling pan-ERR agonist; different profile/popularity) |
| U.S. approval | Not approved (as of November 10, 2026) |
Also known as
- SLU-PP-915 — canonical research designation (St. Louis University Pharmaceutical Program).
- slupp-915 / slu pp 915 / slu-pp915 — compacted or punctuated search spellings of the same name; not a second drug.
- Compound 10s — internal series number in the ACS/medicinal-chemistry identification paper.
- SLU-PP-332 — related but distinct pan-ERR agonist often featured in endurance/exercise-mimetic coverage; do not collapse the two.
AI and forums sometimes invent a second entity from the compacted spelling or file it under peptides. Slupp-915 = SLU-PP-915, and it is a small-molecule ERR agonist.
How is SLU-PP-915 classified?
Preclinical / chemical-biology research tool — synthetic pan-ERR agonist. On this site it sits in the glp1-metabolic cluster for educational comparison with other “exercise mimetic” and metabolic curiosities — with an explicit not-a-peptide banner.
It is not a dietary supplement, not an approved drug, and not the same entity as SLU-PP-332.
What is SLU-PP-915 not?
| SLU-PP-915 is not… | Why that matters |
|---|---|
| A peptide | Different chemistry (nuclear-receptor small molecule) |
| An estrogen / ER hormone drug | ERRs are related orphan receptors — not the same as classical ER agonists |
| Identical to SLU-PP-332 | Sibling series member; different compound |
| FDA-approved | No label |
| A proven safe “cardarine replacement” | Different target; thin human evidence; sport risk hedges |
| Something we dose or source | Refusal |
How is SLU-PP-915 thought to work?
Estrogen-related receptors (ERRs) are orphan nuclear receptors that regulate transcriptional programs for mitochondrial function, oxidative metabolism, and energy homeostasis. Pan-agonists aim to activate ERRα, ERRβ, and ERRγ. Research interest frames this as a potential exercise-mimetic / metabolic pathway — conceptually adjacent to, but distinct from, PPARδ agonism (cardarine) and AMPK activation (ATX-304 / AICAR-class tools).
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Chemistry / in vitro | Identification, binding/co-transfection, gene expression | Cell |
| In vivo (non-human) | Gene-expression / pharmacology follow-up in the series | Animal |
| Human clinical efficacy/safety RCTs | Not established as an approved therapeutic program in this draft | None / thin |
| Anti-doping analytical | In vitro metabolism & LC-HRMS characterization papers (with SLU-PP-332) | Analytical — not efficacy evidence |
| Approved U.S. label | None | None |
Avoid inventing human endurance % improvements or therapeutic doses.
What has SLU-PP-915 been studied for?
Primarily tool-compound pharmacology: ERR target-gene regulation and series SAR (structure–activity) with metabolic/exercise-phenotype rationale shared with related ERR agonists. Anti-doping research studies detection and metabolites because of performance-enhancement concern. Studied as a research ligand ≠ approved therapy.
What safety topics come up?
Human clinical safety packages comparable to approved drugs are not what this entity has in the public evidence ladder summarized here. Nuclear-receptor agonists can have broad transcriptional effects; unknown long-term risk is a core literacy point. Unregulated vendor products: unknown identity/purity. Not medical advice.
What is SLU-PP-915's regulatory status?
- U.S.: Not FDA-approved.
- Sport: Anti-doping literature explicitly discusses SLU-PP-332 and SLU-PP-915 as compounds with doping potential and publishes detection methods. Whether a given WADA list names SLU-PP-915 in a specific calendar year can change — do not rely on forum screenshots. Check current WADA Prohibited List and GlobalDRO. Non-approved substance (S0) and metabolic-modulator class interpretations are commonly discussed in secondary literacy.
- Gray market: Research-chemical marketing is not a clinical pathway.
Why doesn't this page include a dosage chart?
No approved labeled dose; evidence is research-tool grade; “slu-pp-915 dosage” / “slupp-915 cycle” queries seek gray-market protocols. Literacy refusal.
Related lab literacy
Peptide reconstitution pages are not applicable. Cluster primer: What are peptides?
Related compounds and comparisons
- SLU-PP-332 — related pan-ERR agonist (often the better-known exercise-mimetic headline compound); do not equate doses or identity.
- Cardarine (GW501516) — PPARδ agonist (different receptor; discontinued + WADA-classic toxicity story).
- ATX-304 — AMPK network activator investigational small molecule.
- Tesofensine — monoamine reuptake investigational agent (not a peptide).
- Semaglutide / Tirzepatide — approved peptide incretin drugs (different class).
Frequently asked questions
Is SLU-PP-915 a peptide?
No. It is a small-molecule pan-ERR agonist.
Is “slupp-915” a different compound?
No. It is a compacted search spelling of SLU-PP-915. Treat them as the same research designation unless a primary source shows otherwise.
What does SLU-PP mean?
In this series it denotes the St. Louis University Pharmaceutical Program compound numbering — not a peptide abbreviation.
Is SLU-PP-915 the same as SLU-PP-332?
No. They are related pan-ERR agonists from the same research ecosystem/series family, but they are distinct chemical tools. Popular coverage often features SLU-PP-332; that does not make 915 identical.
Is SLU-PP-915 FDA approved?
No, not as of November 10, 2026.
Is it banned in sports?
Anti-doping scientists have characterized it for detection because of doping potential. Exact list naming can vary by year — athletes must check the current WADA list and GlobalDRO rather than screenshots.
Why is this on a peptide tutorials site?
Exercise-mimetic and metabolic search demand clusters ERR tools with peptides. We publish a literacy profile with naming + chemistry-class correction.
Why no dosage information?
YMYL policy and lack of approved labeling. We will not invent a research-chem cycle chart.
SLU-PP-915 is not a peptide and is not FDA-approved. “Slupp-915” is a search spelling of the same name. Educational only. Disclaimer.
Sources
The sources below were checked against PubMed, DailyMed, or the official agency page on November 10, 2026 (America/Phoenix). Links go to the publisher, PubMed, or the agency record.
- Primary — animal Billon C, Appourchaux K, Cote I, Burris TP. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026. doi:10.1016/j.jpet.2025.103787. PMID: 41421047. Preclinical (non-human) study.
- Related analog — animal Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023. doi:10.1021/acschembio.2c00720. PMID: 36988910. Preclinical study of the related analog SLU-PP-332.
- Anti-doping World Anti-Doping Agency. The World Anti-Doping Code International Standard Prohibited List 2026. Accessed November 10, 2026. Confirm the current list and GlobalDRO before relying on sport status. SLU-PP-915 was not named on the 2026 list page we checked. Check the current list and GlobalDRO rather than forum screenshots. Published efficacy work remains preclinical.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Oct 6, 2026 · Regulatory and sport-status wording checked November 10, 2026 against current FDA labels and the 2026 WADA Prohibited List · How we source & update
Educational disclaimer: Educational only. SLU-PP-915 (“slupp-915”) is not a peptide and is not FDA-approved. No dosing or buy links. We don’t sell peptides. Read our full disclaimers.